Skip to content

Clinical trials

Phase 2 Diabetes Mellitus, Type 2 trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus, Type 2 Phase: Phase 2 Country / region: United States Clear all

384 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20012
20024
20034
200410
200517
200618
200725
200827
200932
201021
201122
201213
201313
201416
201518
201613
201713
201817
20198
202010
202110
202215
20239
202410
202516
202616

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed293
Terminated43
Recruiting20
Active, not recruiting13
Withdrawn6
Unknown status5
Not yet recruiting3
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Eli Lilly and Company32
AstraZeneca22
Novo Nordisk A/S18
GlaxoSmithKline16
Hoffmann-La Roche16
Pfizer16
Boehringer Ingelheim8
Novartis Pharmaceuticals8
Takeda7
Mayo Clinic6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus, Type 2384
Diabetes Mellitus74
Obesity39
Insulin Resistance19
Non-alcoholic Fatty Liver Disease18
Diabetes Mellitus, Type 116
Renal Insufficiency, Chronic16
Overweight15
Diabetic Nephropathies11
Glucose Metabolism Disorders11

Trials

Showing 1 to 25 of 384. Each trial links to its page on Pharma Observatory.

284 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.